Australian (ASX) Stock Market Forum

ALA - Arovella Therapeutics

Jump to new
Go ZulpiMist... whatever that is....:confused:
5 day chart.

Screenshot_20200729-190714.png
 
frugal.rock said:
Go ZulpiMist... whatever that is....:confused:
5 day chart.
Click to expand...

Wow!

Oral spray for insomnia. Market cap after today's rise is still only around $18 million I think.

Extension of cap raise time frame just prior to todays good news.

Shares on offer at 2.5 cents cap raise. Closed today at 6.4 cents.

(Tongue in cheek) I wonder if anyone will take up their entitlements?:D

Once the profit takers do their stuff, this has every reason to continue higher in the future given their high cash to market cap ratio.

Wish I held ... don't:(
 
barney said:
Shares on offer at 2.5 cents cap raise. Closed today at 6.4 cents.
Click to expand...
still only around 5c. Up, down and sideways

Company Highlights
▪ Recent Acquisition of a Novel iNKT Cell Therapy Platform: SUDA secured a global licence to a novel invariant natural killer T (iNKT) cell therapy platform from Imperial College London. It is initially being developed for the treatment of blood cancers
▪ Developing Anagrelide for the Treatment of Cancer: SUDA holds the only patents for use of anagrelide for the treatment of metastatic disease. We anticipate the oral spray to be a safer product for the treatment of cancer
▪ Secured an Australian Partner to Commercialise ZolpiMist® for the Treatment of Insomnia: ZolpiMist received TGA approval in July 2020 for the treatment of short-term insomnia. SUDA signed an agreement with the multinational pharmaceutical company, STADA, for Australia with an option for New Zealand.
▪ Unique Platform Technology – OroMist™: Reformulate existing billion-dollar drugs for oral spray delivery, which may create a faster path to market and cost and time savings

SUDA’s Focus For 2021
▪ ZolpiMist commercialization (Teva, STADA, other territories)
▪ Integrate and develop new technologies – iNKT Cell Therapy Platform
▪ Identify and acquire new platform technologies
▪ Anagrelide formulation stabilisation
▪ Early-stage feasibility development work

Cash (30 June 2021) ... $6.7 million
 
And about to change name to Arovella (at EGM). New flush of energy. But a bit scattershot; oral sprays and cancer therapy.
 
On October 25th, 2021, Suda Pharmaceuticals Limited (SUD) changed its name and ASX code to Arovella Therapeutics Limited (ALA).
 
Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human disease. Arovella’s two focus areas are oncology and conditions that impact the central nervous system. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers.

The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Arovella’s product pipeline includes an oral spray for the plateletlowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. Arovella has rights to the product outside of the US and Canada.

Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy
 
I failed to understand the potential of ALA's cell therapy platform.
Passed over the HVBBs that appeared in my charts and the eventual break-out > 0.04.

ala1404.PNG
 
I have picked ALA for the September Monthly Comp.

This caught my eye on Wednesday night after the breakout of the 0.054 level with higher volume. The Bollinger Bands are expanding, it's outperforming the XAO atm, so what's not to like.
Will it continue like it did earlier this year in April ? .... Is it's run over already ? ..... I guess only time will tell.
Geez it's only got to continue for another 21 trading days, that's not too much to ask is it ?

Screenshot 2023-09-01 070320.png
 
Pick for the yearly competition. Has gone on a bit of a run already last year, but I think their process of producing their invariant natural killer T cells has great promise for the treatment of cancers. Hopefully will also translate to a good increase in share price.
 
Quarterly out yesterday, not much new information, progressing with manufacturing larger quantities of ALA-101 for the start of their clinical trials this HY.
They calculated that they had enough funds for 7.4 quarters, however this was worked on expenditure after including the research refund from the government. When you look at their normal cash deficit, they will probably have to raise within this half year.
 
15% lift today after reporting a new licensing agreement with University of North Carolina for incorporating their cytokine technology for their CAR-iNKT platform, resulting in a 10 times increase in numbers in solid tumours. Patent has been applied for with protection for 20 years. No upfront fees, but milestone fees of $10 million, single digit royalty fees and annual license maintenance fees.
Looks like quite a coup for them.
 
Shareprice slowly improving, though their cash must be slowly getting depleted although a few options are getting exercised which might put off the capital raising for a while. Nothing much new in the HY report apart from the slow cash burn.
 
Back to 15c already after raising at 10c with an attaching 15c option. Was hoping for a bit of buying opportunity but seems to be heavy demand for their shares.
 

Similar threads

System
SAS - Sky and Space Company
2 3
Replies
53
Views
16K
greggles
greggles
System
AB1 - Animoca Brands Corporation
Replies
15
Views
7K
she'll be right
S
System
G79 - Goldoz Limited
Replies
7
Views
6K
System
System
System
BIG - Big Un Limited
2 3
Replies
51
Views
19K
noirua
noirua
System
TKF - TikForce Limited
Replies
0
Views
4K
System
System
Top